Executive Vice President and Chief Business Officer
Edward Koval has served as our Executive Vice President and Chief Business Officer since December 2021.
Previously, he was Chief Business Officer at ZebiAI Therapeutics, a company spun out of X-Chem Pharmaceuticals, which was recently acquired by Relay Therapeutics. Prior to the spin-out of ZebiAI from 2013 to 2020, he was Senior Vice President, Corporate Development, at X-Chem Pharmaceuticals, where he closed multiple transactions with multinational pharmaceutical companies for programs in oncology, hematology/oncology, inflammation, infectious disease and rare diseases.
From 2012 to 2015, Mr. Koval served as an independent corporate and business development consultant, advising multiple private and public biotech companies on partnering and fundraising. Mr. Koval’s prior pharmaceutical experience from 1992 to 2012 includes serving roles in business and corporate development, strategic planning, alliance management and financial evaluation and analysis at Novartis Pharmaceuticals Corporation, Merck & Co., Inc. and Chiron Corporation, where he finalized negotiations and executed and managed multiple strategic corporate partnerships and alliances. Mr. Koval holds an M.Sc. in Engineering from Rensselaer Polytechnic Institute and an M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology.